Effect of a solar-powered spatial emanator on malaria prevalence in Uganda (Mossie-GO trial): A double-blinded, cluster-randomised, and placebo-controlled trial
7 affiliations
- 1Digital Odour Technologies Ltd, Dagenham, United Kingdom
- 2Malaria Consortium, Kampala, Uganda
- 3Department of Disease Control, London School of Hygiene & Tropical Medicine, London, United Kingdom
- 4Kua Solar Ltd, London, United Kingdom
- 5Department of Chemistry, Loughborough University, Loughborough, Leicestershire, United Kingdom
- 6Africa Power Ltd, Cowfold, United Kingdom
- 7Department of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, United Kingdom
Abstract
The continued threat of malaria has driven investigations into the efficacy of a range of new tools, including spatial emanators which release active ingredients that can affect mosquito host-seeking vector behaviour and reduce human contact. This study aimed to estimate the effect of a novel solar-powered spatial emanator in reducing the prevalence of malaria in rural and peri-urban settings. The Mossie-GO trial was a prospective, cluster-randomised, controlled trial conducted in Jinja and Buikwe in Eastern Uganda. Fifty-six clusters were randomised at a 1:1 ratio to receive either the spatial emanator with transfluthrin-treated ‘coins’ or an identical device with no-active ingredient. Up to 100 houses per cluster were enrolled. Investigators, field staff, and study participants were masked to cluster allocation. The primary outcome was malaria infection prevalence among children aged ≤5 years at 12 months, compared between intervention and control clusters and adjusted for baseline cluster-level prevalence. The trial was registered with ClinicalTrials.gov (NCT06232954). The baseline-adjusted analysis did not show evidence of lower malaria infection prevalence in intervention clusters compared with control clusters at follow-up. The unadjusted OR for malaria infection was 0.63 (95% CI: 0.29–1.36, p = 0.239), and the baseline-adjusted OR was 0.96 (95% CI: 0.66–1.39, p = 0.813). No significant differences in mosquito density were observed. No serious adverse events were reported and there was no difference in the rate of adverse events between trial arms. The trial did not demonstrate significantly lower follow-up malaria infection prevalence in intervention clusters after adjustment for baseline cluster-level prevalence. Exploratory subgroup analyses reveal some indication of change and should be interpreted as hypothesis-generating. There was also an observed but not significant reduction in human biting rate in intervention households. Large variation in baseline data and between clusters may have limited the power of the study to detect significant results.
Related
- Effect of different forms of upper limb muscle training on dyspnea in chronic obstructive pulmonary disease: a randomised controlled trial
- Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial
- Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial
- Chlorhexidine plus alcohol versus povidone iodine plus alcohol, combined or not with innovative devices, for prevention of short-term peripheral venous catheter infection and failure (CLEAN 3 study): an investigator-initiated, open-label, single centre, randomised-controlled, two-by-two factorial trial
- Protecting mothers and their infants through screening and comprehensive management of sexually transmitted infections in antenatal care in Zimbabwe (PROMISE): study protocol for an open label individually randomised controlled trial.
BibTeX
@article{dennehy2026effect,
title = {{Effect of a solar-powered spatial emanator on malaria prevalence in Uganda (Mossie-GO trial): A double-blinded, cluster-randomised, and placebo-controlled trial}},
author = {Jessica Dennehy and Will Dyall and Akin Jenkins and Asadu Sserwanga and Ruth Kigozi and Justine Babirye and John Baptiste Bwanika and Megan Arnett and James Oduor and Anthony Nuwa and Peter Ojangole and Henry D. Mawejje and Matthew A. Turner and Richard Wallace and Frederick G. A. Lyle and Jeff Hebden and John Bradley and Alexandra Hiscox and James G. Logan and Jane Achan and Alastair K. Livesey and Robert T. Jones},
journal = {PLOS Global Public Health},
year = {2026},
month = nov,
doi = {10.1371/journal.pgph.0007457},
url = {https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007457},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Effect of a solar-powered spatial emanator on malaria prevalence in Uganda (Mossie-GO trial): A double-blinded, cluster-randomised, and placebo-controlled trial
AU - Jessica Dennehy
AU - Will Dyall
AU - Akin Jenkins
AU - Asadu Sserwanga
AU - Ruth Kigozi
AU - Justine Babirye
AU - John Baptiste Bwanika
AU - Megan Arnett
AU - James Oduor
AU - Anthony Nuwa
AU - Peter Ojangole
AU - Henry D. Mawejje
AU - Matthew A. Turner
AU - Richard Wallace
AU - Frederick G. A. Lyle
AU - Jeff Hebden
AU - John Bradley
AU - Alexandra Hiscox
AU - James G. Logan
AU - Jane Achan
AU - Alastair K. Livesey
AU - Robert T. Jones
PY - 2026
DA - 2026/11/05
JO - PLOS Global Public Health
DO - 10.1371/journal.pgph.0007457
UR - https://journals.plos.org/globalpublichealth/article?id=10.1371/journal.pgph.0007457
AB - The continued threat of malaria has driven investigations into the efficacy of a range of new tools, including spatial emanators which release active ingredients that can affect mosquito host-seeking vector behaviour and reduce human contact. This study aimed to estimate the effect of a novel solar-powered spatial emanator in reducing the prevalence of malaria in rural and peri-urban settings. The Mossie-GO trial was a prospective, cluster-randomised, controlled trial conducted in Jinja and Buikwe in Eastern Uganda. Fifty-six clusters were randomised at a 1:1 ratio to receive either the spatial emanator with transfluthrin-treated ‘coins’ or an identical device with no-active ingredient. Up to 100 houses per cluster were enrolled. Investigators, field staff, and study participants were masked to cluster allocation. The primary outcome was malaria infection prevalence among children aged ≤5 years at 12 months, compared between intervention and control clusters and adjusted for baseline cluster-level prevalence. The trial was registered with ClinicalTrials.gov (NCT06232954). The baseline-adjusted analysis did not show evidence of lower malaria infection prevalence in intervention clusters compared with control clusters at follow-up. The unadjusted OR for malaria infection was 0.63 (95% CI: 0.29–1.36, p = 0.239), and the baseline-adjusted OR was 0.96 (95% CI: 0.66–1.39, p = 0.813). No significant differences in mosquito density were observed. No serious adverse events were reported and there was no difference in the rate of adverse events between trial arms. The trial did not demonstrate significantly lower follow-up malaria infection prevalence in intervention clusters after adjustment for baseline cluster-level prevalence. Exploratory subgroup analyses reveal some indication of change and should be interpreted as hypothesis-generating. There was also an observed but not significant reduction in human biting rate in intervention households. Large variation in baseline data and between clusters may have limited the power of the study to detect significant results.
SN - 2767-3375
ER -